v3.26.3
Other (Income)/Deductions—Net - Schedule of Other (Income)/Deductions—Net (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 27, 2026
Sep. 28, 2025
Sep. 27, 2026
Sep. 28, 2025
Other Income and Expenses [Abstract]        
Interest income $ (108) $ (138) $ (336) $ (437)
Interest expense 662 652 1,998 1,960
Net interest expense 554 514 1,662 1,523
Net (gains)/losses on asset disposals (132) (2) (150) (91)
Net (gains)/losses recognized during the period on equity securities [1] 75 (201) 121 94
Income from collaborations, out-licensing arrangements and sales of compound/product rights (111) (45) (165) (82)
Net periodic benefit costs/(credits) other than service costs (103) (73) (258) (333)
Certain legal matters, net [2] 13 191 1,047 755
Certain asset impairments [3] 0 260 4,325 577
Net gain from the sale of investment in ViiV [4] 0 0 (1,870) 0
Changes in fair value of contingent consideration liabilities [5] 159 15 709 57
Other, net [6] (167) (141) (556) (291)
Other (income)/deductions––net $ 288 $ 517 $ 4,866 $ 2,210
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The amount for the first nine months of 2026 primarily includes certain product liability and other legal expenses. The amount for the third quarter of 2025 primarily included certain product liability expenses. The amount for the first nine months of 2025 primarily included certain product liability and other legal expenses.
[3] The amount for the first nine months of 2026 represents intangible asset impairment charges associated with our Biopharma segment, composed of: (i) $3.8 billion in impairments of IPR&D assets associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results, and (ii) $525 million for Oxbryta (voxelotor) developed technology rights, after engaging with the FDA in July 2026 to discuss their assessment of data and analyses, and it was determined there was no viable pathway to return Oxbryta to the market in the U.S. The amounts for the third quarter and first nine months of 2025 included an intangible asset impairment charge associated with our Biopharma segment of $260 million related to IPR&D associated with a Phase 3 study for inclacumab for the treatment of SCD, which reflected unfavorable clinical trial results. The amount for the first nine months of 2025 also included an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
[4] See Note 2C.
[5] See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.
[6] The amounts for the third quarter and first nine months of 2026 include, among other things, dividend income of $58 million and $239 million, respectively, from our previous investment in ViiV. The amounts for the third quarter and first nine months of 2025 included, among other things, dividend income of $72 million and $184 million, respectively, from our previous investment in ViiV.